Pair Name | Vitamin C, Anti-PD-1 antibody | |||
Partner Name | Vitamin C | |||
Disease Info | [ICD-11: 2B33.5] | Lymphoma | Investigative | |
Biological Phenomena | Inhibition-->Anti-PD1 checkpoint | |||
Gene Regulation | Up-regulation | Expression | GZMB | hsa3002 |
Up-regulation | Expression | IL12B | hsa3593 | |
In Vitro Model | A20 | Reticulum cell sarcoma | Mus musculus (Mouse) | CVCL_1940 |
SU-DHL-6 | Diffuse large B-cell lymphoma germinal center B-cell type | Homo sapiens (Human) | CVCL_2206 | |
OCI-Ly1 | Diffuse large B-cell lymphoma | Homo sapiens (Human) | CVCL_1879 | |
OCI-Ly7 | Diffuse large B-cell lymphoma germinal center B-cell type | Homo sapiens (Human) | CVCL_1881 | |
OCI-Ly3 | Diffuse large B-cell lymphoma activated B-cell type | Homo sapiens (Human) | CVCL_8800 | |
In Vivo Model | 40 BALB/c mice received a subcutaneous (s.c.) right flank injection of 5×10⁶ A20 tumor cells in phosphate-buffered saline (PBS) and were randomly assigned to 4 groups of 10 mice: vehicle, anti-PD1 (α-PD1), AA, and AA+α-PD1. | |||
Result | This study shows that AA treatment 1) increases immunogenicity of lymphoma cells; 2) enhances intratumoral infiltration of CD8+ T cells and macrophages; and 3) synergizes with anti-PD1 checkpoint inhibition in a syngeneic lymphoma mouse model via marked activation of cytotoxic cells (cytotoxic T cells and NK cells) and antigen presenting cells. The data provide a compelling rationale for testing combinations of high-dose AA and anti-PD1 agents in patients with aggressive B cell lymphoma and in preclinical models of other malignancies. |
Pair Name | Quercetin, Anti-PD-1 antibody | |||
Partner Name | Quercetin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Reshaped-->Tumor immune microenvironment | |||
Gene Regulation | Up-regulation | Expression | ARG1 | hsa383 |
Up-regulation | Expression | CD4 | hsa920 | |
Up-regulation | Expression | CD8A | hsa925 | |
Up-regulation | Expression | IFNG | hsa3458 | |
Up-regulation | Expression | IL10 | hsa3586 | |
Down-regulation | Expression | IL12A | hsa3592 | |
Down-regulation | Expression | IL1B | hsa3553 | |
Down-regulation | Expression | IL4 | hsa3565 | |
Down-regulation | Expression | IL6 | hsa3569 | |
Up-regulation | Expression | ITGAM | hsa3684 | |
Up-regulation | Expression | MMP9 | hsa4318 | |
Down-regulation | Expression | NFKBIA | hsa4792 | |
Down-regulation | Expression | RELA | hsa5970 | |
Up-regulation | Expression | TGFB1 | hsa7040 | |
Down-regulation | Expression | TLR4 | hsa7099 | |
Down-regulation | Expression | TNF | hsa7124 | |
In Vivo Model | Orthotopically transplanted HCC tumors in mice were treated with quercetin, anti-PD-1 antibody, or a combination of both therapies. | |||
Result | Quercetin/anti-PD-1 antibody combination therapy reshaped HCC tumor microenvironment in mice in parallel with regulating the GM and macrophage immunity. |
Pair Name | Lycopene, Anti-PD-1 antibody | |||
Partner Name | Lycopene | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Immunomodulatory | |||
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | CXCL10 | KEGG ID N.A. | |
Up-regulation | Expression | CXCL9 | KEGG ID N.A. | |
Down-regulation | Expression | DNMT3A | KEGG ID N.A. | |
Up-regulation | Expression | IFNG | hsa3458 | |
Up-regulation | Expression | IRF1 | hsa3659 | |
Up-regulation | Expression | IRF7 | KEGG ID N.A. | |
Up-regulation | Phosphorylation | JAK2 | hsa3717 | |
Down-regulation | Expression | PD-L1 | KEGG ID N.A. | |
Up-regulation | Phosphorylation | STAT3 | hsa6774 | |
In Vitro Model | 3LL | Malignant tumors of the mouse pulmonary system | Mus musculus (Mouse) | CVCL_5653 |
In Vivo Model | Lewis lung carcinoma (LLC) cells (1×10⁶) were injected in the rear flak of C57BL/6 mice | |||
Result | lycopene promoted anti-PD-1 therapeutic efficiency of lung cancer by promoting IFNγ-expressing CD8+ cells infiltrated in tumor tissues and increasing IFNγ expression in tumor cells. |
Pair Name | Curcumin, Anti-PD-1 antibody | |||
Partner Name | Curcumin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Immune evasion | |||
Gene Regulation | Down-regulation | Expression | EP300 | hsa2033 |
Down-regulation | Activity | SMAD2/3 | KEGG ID N.A. | |
Down-regulation | Expression | TGFB1 | hsa7040 | |
In Vitro Model | Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 |
In Vivo Model | Hep3B cells in the logarithmic growth phase were suspended in 50% Matrigel (BD Biosciences) and adjusted to a density of 2×10⁶ cells/mL, and 0.2 mL of single-cell suspension was subcutaneously injected into the left axilla of each mouse. | |||
Result | Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma |
Pair Name | Carnosic acid, Anti-PD-1 antibody | |||
Partner Name | Carnosic acid | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Immunomodulatory | |||
Gene Regulation | Down-regulation | Expression | CTNNB1 | hsa1499 |
Down-regulation | Expression | GSK3B | hsa2932 | |
Down-regulation | Expression | WNT3A | hsa89780 | |
In Vitro Model | MHCC97-H | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_4972 |
In Vivo Model | MHCC97H cells (4×10⁶ cells/site) were implanted subcutaneously into hip of four- to five-week-old male athymic nude mice. | |||
Result | CA-NBF combined with anti-PD-1 have stronger immunomodulatory and anticancer effects without increasing biological toxicity. |
No. | Title | Href |
---|---|---|
1 | Carnosic acid nanocluster-based framework combined with PD-1 inhibitors impeded tumorigenesis and enhanced immunotherapy in hepatocellular carcinoma. Funct Integr Genomics. 2024 Jan 6;24(1):5. doi: 10.1007/s10142-024-01286-2. | Click |
2 | High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1666-1677. doi: 10.1073/pnas.1908158117. | Click |
3 | Quercetin/Anti-PD-1 Antibody Combination Therapy Regulates the Gut Microbiota, Impacts Macrophage Immunity and Reshapes the Hepatocellular Carcinoma Tumor Microenvironment. Front Biosci (Landmark Ed). 2023 Dec 1;28(12):327. doi: 10.31083/j.fbl2812327. | Click |
4 | Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. Cancer Cell Int. 2019 Mar 21;19:68. doi: 10.1186/s12935-019-0789-y. | Click |
5 | Synergistic efficacy of curcumin and anti-programmed cell death-1 in hepatocellular carcinoma. Life Sci. 2021 Aug 15;279:119359. doi: 10.1016/j.lfs.2021.119359. | Click |